Indications for intra-venous immunoglobulin treatment in rheumatic diseases
Con l’immissione in commercio delle Immunoglobuline per uso endovenoso (IVIG), che risale ormai al 1981, è stato possibile ampliarne enormemente le utilizzazioni terapeutiche, dimostrando l’efficacia di tale trattamento in condizioni cliniche le più diverse. In particolare, sulla base della progress...
Main Authors: | F. Laghi Pasini, P.L. Capecchi, F. Bellisai, P.E. Lazzerini, M. Galeazzi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2003-12-01
|
Series: | Reumatismo |
Online Access: | https://reumatismo.org/index.php/reuma/article/view/132 |
Similar Items
-
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
by: Lazzerini PE, et al.
Published: (2016-09-01) -
The place of intravenous immunoglobulin in rheumatic diseases
by: N. V. Seredavkina, et al.
Published: (2016-01-01) -
Long QT syndrome: an emerging role for inflammation and immunity
by: Pietro Enea eLazzerini, et al.
Published: (2015-05-01) -
Commentary: Systemic effects of IL-17 in inflammatory arthritis
by: Pietro Enea Lazzerini, et al.
Published: (2019-12-01) -
Intravenous immunoglobulin: prospects in patients with autoimmune rheumatic diseases
by: Elena Aleksandrovna Aseeva, et al.
Published: (2014-03-01)